Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Research in Real-Life Ltd
With
Teva Pharmaceuticals USA
Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to fewer exacerbations than management adhering to Global Initiative for Asthma (GINA) guidelines. However the use of sputum to measure eosinophil levels is expensive and impractical within a clinical setting. This study explores the use of blood-eosinophil levels as a clinical predictor for exacerbations and asthma control within a UK primary care dataset.
Age
12–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient aged 12-80 at date of last eosinophil count
Asthma diagnosis at any time
Blood Eosinophil reading in patient record (numeric count expressed in µl) at least one year prior to last data extraction